[ad_1]
By Robb M. Stewart
Moderna Inc. said Thursday it is taking the first step in its new respiratory vaccine program with the development of a single-dose vaccine that combines a Covid-19 booster and an influenza booster.
The combined vaccine candidate, known as mRNA-1073, combines Moderna’s Covid-19 vaccine and its influenza vaccine candidate. MRNA-1073 encodes the Covid-19 spike protein and influenza HA glycoproteins, the company said in a statement for its 2021 research and development day.
Moderna has 37 programs in development out of 34 candidates for development, including 22 in ongoing clinical studies, he said.
The company said it is working on a next-generation vaccine against Covid-19, mRNA-1283, and that an early stage study is fully registered. The vaccine encodes the parts of the SARS-CoV-2 spike protein that the company says are essential for neutralization, and is under development as a potential refrigerator-stable mRNA vaccine that will allow distribution. and easier administration by health care providers.
Moderna also said it is tackling the worrisome variants of Covid-19 and has four development candidates, including three that were administered in a Phase 2/3 clinical trial and the start of a clinical cohort with the fourth. candidate is expected in the coming weeks. Moderna said its strategy is to develop booster vaccines against current variants of concern and against future potential variants of concern.
The company said it has submitted a booster dose, or a third, of its Covid-19 vaccine at the dose level of 50 ug for emergency use authorization to the United States Food and Drug Administration, for conditional marketing approval with the European Medicines Agency and other regulatory bodies.
Moderna received approval to use its Covid-19 vaccine in adolescents aged 12 and over in the European Union and other jurisdictions, and on August 25, it completed the continuous submission process of a biologics license application for the vaccine in the United States. The phase 2 study of mRNA-1273 in children aged 6 months to 11 years is ongoing.
Moderna said its cash flow at the end of August was around $ 15 billion.
Write to Robb M. Stewart at [email protected]
Source link
